MedTrace Logo

PET Imaging of Giant Cell and Takayasu Arteritis

NCT04071691 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 27

Last updated 2024-07-22

No results posted yet for this study

Summary

While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging is often included in the diagnostic work-up of patients with large-vessel vasculitis (LVV), 18F-FDG lacks specificity for inflammatory cells and has limited ability to track therapy response. Moreover, high background 18F-FDG uptake in the brain and myocardium largely precludes imaging temporal arteritis in giant-cell arteritis (GCA) and coronary artery involvement in Takayasu arteritis respectively. These limitations of 18F-FDG for imaging LVV highlight important unmet clinical needs, which might be overcome by using a somatostatin receptor subtype-2 (SST2) PET tracer.

Conditions

  • Giant Cell Arteritis
  • Takayasu Arteritis

Interventions

DIAGNOSTIC_TEST

PET-MRI

SST2 PET-MRI scan

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • Wellcome Trust

    collaborator OTHER

  • Imperial College London

    collaborator OTHER

  • National Institute for Health Research, United Kingdom

    collaborator OTHER_GOV

  • University of Cambridge

    lead OTHER

Principal Investigators

  • Jason M Tarkin, MBBS PhD · University of Cambridge

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-25
Primary Completion
2025-04-30
Completion
2025-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04071691 on ClinicalTrials.gov